Chronic HypoparathyroidismPaTH CVNCT07707479
Cardiovascular Effects of Parathyroid Hormone Analogues in Chronic Hypoparathyroidism
An observational study of Chronic Hypoparathyroidism, run by National and Kapodistrian University of Athens at 2 sites in Greece.
Trial summary
The goal of this study is to evaluate cardiovascular effects of long-acting parathyroid hormone (PTH) analogues in adults with chronic hypoparathyroidism. The main questions it aims to answer are: Do patients with hypoparathyroidism have increased arterial stiffness and markers of subclinical cardiovascular injury… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Chronic Hypoparathyroidism
- What is being tested?
- Arterial stiffness in the aorta by measurement of pulse wave velocity, Central blood pressures and reflected waves in the aorta and Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques
- How many people
- 210 participants
- Where
- 2 sitesGreece
- Study dates
- 1 Apr 2026to 31 Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy or palopegteriparatide for more than one year and comparable healthy individuals, matched to patients based on key characteristics such as age, sex, and cardiovascular risk factors
Who may be able to join
- Cross sectional arm: Baseline State: Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy or palopegteriparatide for more than one year
- -Prospective Follow-up: Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy and about to start treatment with palopegteriparatide willing to undergo baseline measurements (prior to the first dose) and repeat measurements at 3 and 12 months.
Who cannot join
- Renal Function: CKD Stage 3 or higher (eGFR < 60 mL/min/1.73 m²)
- Uncontrolled Risk Factors:
- SBP > 180/100 mmHg
- Uncontrolled endocrine diseases (e.g., hyper- or hypothyroidism, diabetes mellitus type 2 with HbA1c>7.5%).
- Bone Health: Any metabolic bone disease other than hypoparathyroidism (excluding osteoporosis)
- Documented Atrial Fibrillation (ECG)
- Contraindication to long acting PTH analogue as per product labeling
Trial locations and contacts
2 sites in 1 country.
Greece2 sites
Alexandra General Hospital of Athens
Athens, 11527
Medical School, National and Kapodistrian University of Athens, LAIKO General Hospital of Athens
Athens, 11527
About this study
Official title: Effect of Long-acting PTH Analogues on Markers of Subclinical Arterial and Myocardial Injury in Chronic Hypoparathyroidism..
The goal of this study is to evaluate cardiovascular effects of long-acting parathyroid hormone (PTH) analogues in adults with chronic hypoparathyroidism. The main questions it aims to answer are:
- Do patients with hypoparathyroidism have increased arterial stiffness and markers of subclinical cardiovascular injury compared to healthy individuals?
- Does treatment with a long-acting PTH analogue improve vascular and cardiac function over time compared to conventional therapy? This is a multi-center study with two parts: a cross-sectional comparison and a 12-month prospective follow-up. Adults with chronic hypoparathyroidism and matched healthy controls will undergo clinical evaluation, vascular measurements, cardiac imaging, and blood tests.
In the prospective part, patients that just started long-acting PTH analogue therapy based on their treating physicians choice will be followed for 12 months, with repeat assessments at baseline, 3 months, and 12 months to evaluate changes in cardiovascular markers.
Read the detailed description
The goal of this study is to better understand how chronic hypoparathyroidism affects heart and blood vessel health, and whether treatment with a long-acting parathyroid hormone (PTH) analogue can improve cardiovascular function. Hypoparathyroidism is a rare condition in which the body does not produce enough PTH, leading to low calcium levels and possible long-term complications, including an increased risk of cardiovascular disease.
This study aims to answer the following main questions:
Do people with chronic hypoparathyroidism have early (subclinical) signs of damage to the heart and blood vessels compared to people without the condition? Does treatment with a long-acting PTH analogue improve vascular health and reduce early markers of cardiovascular disease over time?
The study includes two parts. In the first part, researchers will compare adults with hypoparathyroidism-either receiving standard treatment (calcium and vitamin D) or long-acting PTH therapy-with healthy individuals of similar age and health characteristics. Participants that will undergo the non-invasive tests to assess blood vessel stiffness, blood pressure, microcirculation, and heart function, along with blood tests to measure calcium balance and cardiovascular biomarkers, as part of routine clinical practice will be eligible for the study.
In the second part, participants with hypoparathyroidism who are starting treatment with a long-acting PTH analogue will be followed for 12 months. They will be evaluated at the beginning of the study, at 3 months and again at 12 months. Researchers will track changes in blood vessel function, heart performance, and biochemical markers to determine whether restoring normal PTH levels improves cardiovascular health.
All participants will undergo detailed clinical assessments, including imaging of blood vessels and the heart, as well as laboratory testing. The findings from this study may help improve understanding of cardiovascular risk in hypoparathyroidism and guide future treatment strategies.
- Conditions
- Chronic Hypoparathyroidism
- Being tested
- Arterial stiffness in the aorta by measurement of pulse wave velocity, Central blood pressures and reflected waves in the aorta, Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques, Imaging of the sublingual microcirculation (GlycoCheck system), Ankle-brachial index (ABI)
- Keywords
- chronic Hypoparathyroidism, palopegteriparatide, subclinical arterial and myocardial injury, cardiovascular disease, concomitant diseases, conventional therapy
- Medical subject headings
- Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Arterial stiffness in the aorta by measurement of pulse wave velocityDiagnostic test
Carotid-femoral pulse wave velocity (c-f PWV) is an established index of aortic stiffness and an independent predictor of worse cardiovascular prognosisIt is considered as the gold standard for assessing aortic stiffness non-invasively and is calculated from measurements of pulse transit time and the distance travelled between 2 recording sites with a validated non-invasive device (Complior, Artech Medical, France). Two different pulse waves are obtained at the same time transcutaneously with the patient in a supine position at 2 sites, at the right common carotid artery and the right femoral artery (i.e. 'carotid-femoral' PWV) by using pressure-sensitive transducers.
Central blood pressures and reflected waves in the aortaDiagnostic test
Non-invasive estimation of aortic pressure waveforms and reflected waves by pulse wave analysis (PWA) will be performed in the Angiology laboratory by the SphygmoCor System (AtCor Medical Pty Ltd, Sydney, Australia). The radial artery is gently and steadily compressed against the underlying bone, thus flattening it and equalizing circumferential pressures, allowing radial pressure waves to be recorded by a high fidelity micromanometer placed on the tip of a hand - held tonometer the size of a pen (Millar). Optimal recording is obtained if the wrist is bent outward and supported by using a small cushion or the operator's hand.
The following indices are measured:
- augmentation index (AI, percentage) normalized for the heart rate of 75 bpm, expressed as a percentage of the aortic pulse pressure,
- central systolic and diastolic pressures (cBP),
- time to the beginning of the reflected wave (in milliseconds) and
- blood pressure amplification calculated as the ratio of peripheral
Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaquesDiagnostic test
B-mode ultrasound examination will also be performed, using a 14.0 MHz multi-frequency linear array probe attached to a high-resolution ultrasound machine (Vivid 7 Pro, GE Healthcare, USA). All scans are going to be performed by the same operator. Carotid intima-media thickness (ccIMT) will be measured at the distal 1.0 cm of the common carotid proximal to the bifurcation as previously described (23) . In each segment 3 measurements of the maximal IMT in the far wall will be averaged, after excluding plaque thickness. The average of the maximal IMT will be used in the analyses. Femoral IMT (fIMT) will be measured on each side, scanning a 1cm-long arterial segment proximal to the femoral bifurcation, defined as the common femoral artery segment and the average value of IMT of the far wall will be estimated. A cutoff value of >0.9 mm for mean ccIMT or fIMT will be considered increased. Plaques to carotid and femoral arteries are defined as a focal structure that protrudes into the arteri
Imaging of the sublingual microcirculation (GlycoCheck system)Diagnostic test
The measurement procedure and the calculation of the sublingual microvascular parameters is performed as follows: the probe of a hand-held side-stream darkfield (SDF) videomicroscope (CapiScope HVCS, KK Technology, Honiton, UK) is placed on the sublingual mucosa of the subject, to obtain video recordings of the sublingual microvasculature. Subsequently, an analysis software (the GlycoCheck Measurement System Software Version 5.3.3) selects and analyses SDF images that are of sufficient quality (adequate focus, adequate contrast and limited movement) and automatically calculates the sublingual microcirculation parameters, such as vascular density (VD), red blood cell filling (RBCF), and perfused boundary region (PBR).
Ankle-brachial index (ABI)Diagnostic test
The primary non-invasive test for the diagnosis of lower extremity artery disease (LEAD) is the ABI. A cut-off value of <0.9 will be used for the diagnosis of LEAD and as predictive index of atherosclerosis, associated with increased risk of cardiovascular morbidity and mortality. Also, a cut-off value of >1.40 will be used as an index of stiffened arteries, also associated with increased mortality. For its measurement, a 10-12 cm sphygmomanometer cuff will be placed just above the ankle and a (handheld) Doppler instrument (5-10 MHz) will measure the pressure of the posterior and anterior tibial arteries of each foot. The highest ankle systolic pressure will be divided by the highest brachial systolic pressure, resulting in an ABI per leg.
FundoscopyDiagnostic test
A set of colour and black-and-white fundus images photograph per eye will be taken by well-trained ophthalmic photographers: macula-centered images using the handheld Optomed Aurora fundus cameras without pupil dilation. The images obtained with the handheld fundus camera had a field of view of 50° and 5 mega-pixel resolution
Cardiac Ultrasonography StudyDiagnostic test
Participants will undergo a baseline echocardiographic examination. Standard protocol will be used and standard measurements from 2-D and Doppler echocardiography will be made. LV end-diastolic and end-systolic volumes, as well as ejection fraction, will be derived from the apical 4- and 2-chamber views using the biplane Simpson's rule. Left ventricular mass will be calculated according to Devereux's formula. Doppler examination will include interrogation of mitral inflow, and early (E) and late (A) peak diastolic velocities and deceleration time will be measured. Tissue Doppler analysis will include pulse wave interrogation of the medial and lateral mitral annulus, peak diastolic early E΄ annular velocities will be obtained and the mean value and E/E' will be calculated. In addition, Speckle-tracking analysis will be applied to estimate LV rotational mechanics, and longitudinal strain parameters. Parasternal short-axis views at the level of the mitral valve and apex, and standard apic
Local shear stress in brachial and carotid arteryDiagnostic test
In order to calculate local shear stress in brachial and carotid artery, measurements of mean flow velocity in the lumen of these arteries will be needed. These measurements will be obtained, while performing carotid ultrasonography and FMD in brachial artery, as previously described. In detail, the form to calculate shear stress is: shear stress (in dyn/cm2 ) = 8×μ× mean flow velocity/resting diameter, where μ is the viscosity of blood which was assumed to be 0.035 dyne s/cm2
Peripheral and aortic office and ambulatory blood pressureDiagnostic test
The peripheral and aortic office blood pressure will be assessed using specialized equipment (certified blood pressure monitor). 24-hour Ambulatory Blood pressure monitoring for measurement of 24 hour peripheral and aortic
Circulating levels of myocardial biomarkersDiagnostic test
Fasting venous blood samples will be collected for evaluation of myocardial biomarkers (hs-troponin I, NT-proBNP). Additional samples will be obtained for isolation of PBMCs.
Evaluation of Calcium metabolismDiagnostic test
Fasting venous blood samples will be collected for evaluation of calcium metabolism (PTH, calcium, albumin, magnesium, phosphate, 25-hydroxyvitamin D) .
| Study group | Role | What they receive |
|---|---|---|
| Patients with chronic hypoparathyroidism under conventional treatment (disease control) | 20-30 Hypo-PT patients aged ≥18 on conventional HypoPT therapy with any dose of activated vitamin D and calcium and native vitamin D supplements for at least 12 months Receives: Diagnostic Test: Arterial stiffness in the aorta by measurement of pulse wave velocity; Diagnostic Test: Central blood pressures and reflected waves in the aorta; Diagnostic Test: Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques; Diagnostic Test: Imaging of the sublingual microcirculation (GlycoCheck system); Diagnostic Test: Ankle-brachial index (ABI); Diagnostic Test: Fundoscopy; Diagnostic Test: Cardiac Ultrasonography Study; Diagnostic Test: Local shear stress in brachial and carotid artery; Diagnostic Test: Peripheral and aortic office and ambulatory blood pressure; Diagnostic Test: Circulating levels of myocardial biomarkers; Diagnostic Test: Evaluation of Calcium metabolism | |
| Patients with chronic hypoparathyroidism under treatment with palopegteriparatide | 40-50 Hypo-PT patients aged ≥18 treated with Palopegteriparatide (TransCon PTH) for at least 12 months Receives: Diagnostic Test: Arterial stiffness in the aorta by measurement of pulse wave velocity; Diagnostic Test: Central blood pressures and reflected waves in the aorta; Diagnostic Test: Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques; Diagnostic Test: Imaging of the sublingual microcirculation (GlycoCheck system); Diagnostic Test: Ankle-brachial index (ABI); Diagnostic Test: Fundoscopy; Diagnostic Test: Cardiac Ultrasonography Study; Diagnostic Test: Local shear stress in brachial and carotid artery; Diagnostic Test: Peripheral and aortic office and ambulatory blood pressure; Diagnostic Test: Circulating levels of myocardial biomarkers; Diagnostic Test: Evaluation of Calcium metabolism | |
| Healthy controls | Healthy controls: 170 Healthy controls matched with group 1 and group 2 for age, sex, CVD presence, propensity score, DM2, renal function, BMI and SBP, retrospectively recruited from the Athens Angiometabolic Cohort Receives: Diagnostic Test: Arterial stiffness in the aorta by measurement of pulse wave velocity; Diagnostic Test: Central blood pressures and reflected waves in the aorta; Diagnostic Test: Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques; Diagnostic Test: Imaging of the sublingual microcirculation (GlycoCheck system); Diagnostic Test: Ankle-brachial index (ABI); Diagnostic Test: Fundoscopy; Diagnostic Test: Cardiac Ultrasonography Study; Diagnostic Test: Local shear stress in brachial and carotid artery; Diagnostic Test: Peripheral and aortic office and ambulatory blood pressure; Diagnostic Test: Circulating levels of myocardial biomarkers; Diagnostic Test: Evaluation of Calcium metabolism | |
| Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide | 20 patients starting treatment with palopegteriparatide, previously on conventional treatment Receives: Diagnostic Test: Arterial stiffness in the aorta by measurement of pulse wave velocity; Diagnostic Test: Central blood pressures and reflected waves in the aorta; Diagnostic Test: Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques; Diagnostic Test: Imaging of the sublingual microcirculation (GlycoCheck system); Diagnostic Test: Ankle-brachial index (ABI); Diagnostic Test: Fundoscopy; Diagnostic Test: Cardiac Ultrasonography Study; Diagnostic Test: Local shear stress in brachial and carotid artery; Diagnostic Test: Peripheral and aortic office and ambulatory blood pressure; Diagnostic Test: Circulating levels of myocardial biomarkers; Diagnostic Test: Evaluation of Calcium metabolism |
What is being measured
The primary outcome is the main question the study is designed to answer.
Differences between PTH-treated group, disease control group, and healthy controls in carotid-femoral pulse wave velocity (cfPWV)
Differences in carotid-femoral pulse wave velocity (cfPWV) between patients with hypoparathyroidism receiving conventional therapy, patients treated with long-acting PTH analogue (palopegteriparatide/TransCon PTH), and healthy controls.
Two different pulse waves are obtained at the same time transcutaneously with the patient in a supine position at 2 sites, at the right common carotid artery and the right femoral artery (i.e. 'carotid-femoral' PWV) by using pressure-sensitive transducers. The distance traveled by the pulse wave is measured over the body surface and calculated by subtracting the carotid (sternal notch from the carotid)-femoral distance as distance/time (m/s) .
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline, to 3 and 12 months
Secondary outcomes (22)
Differences between PTH-treated group, disease control group, and healthy controls in central blood pressure
Assessment of differences in central blood pressure between patients treated with long-acting PTH analogue, disease controls on conventional therapy, and healthy controls. 24-hour Ambulatory Blood pressure monitoring for measurement of 24 hour aortic blood pressure will be performed.
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline, to 3 and 12 months
Differences between PTH-treated group, disease control group, and healthy controls in peripheral blood pressure
Assessment of differences in central blood pressure between patients treated with long-acting PTH analogue, disease controls on conventional therapy, and healthy controls. 24-hour Ambulatory Blood pressure monitoring for measurement of 24 hour peripheral blood pressure will be performed.
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline, to 3 and 12 months
Differences between PTH-treated group, disease control group, and healthy controls in carotid intima-media thickness (IMT)
B-mode ultrasound examination will be performed, using a 14.0 MHz multi-frequency linear array probe attached to a high-resolution ultrasound machine (Vivid 7 Pro, GE Healthcare, USA). All scans are going to be performed by the same operator. Carotid intima-media thickness (ccIMT) will be measured at the distal 1.0 cm of the common carotid proximal to the bifurcation. In each segment 3 measurements of the maximal IMT in the far wall will be averaged, after excluding plaque thickness. The average of the maximal IMT will be used in the analyses. A cutoff value of >0.9 mm for mean ccIMT will be considered increased. Plaques to carotid are defined as a focal structure that protrudes into the arterial lumen of at least 0.5 mm or 50
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in sublingual microcirculation parameters (vascular density)
The probe of a hand-held side-stream darkfield (SDF) videomicroscope (CapiScope HVCS, KK Technology, Honiton, UK) is placed on the sublingual mucosa of the subject, to obtain video recordings of the sublingual microvasculature. Subsequently, an analysis software (the GlycoCheck Measurement System Software Version 5.3.3) selects and analyses SDF images that are of sufficient quality (adequate focus, adequate contrast and limited movement) and automatically calculates the sublingual microcirculation parameters, (vascular density (VD). Measurements will be performed by one user, experienced in performing sublingual measurements with this tool. Measurements will be taken with subjects in supine position with the researcher standing behind the headboard. Volunteers will be asked to swallow any saliva prior to measuring after which the camera will be manually placed and held still in the sublingual region.
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in fundoscopic vascular findings.
A set of colour and black-and-white fundus images photograph per eye will be taken by well-trained ophthalmic photographers: macula-centered images using the handheld Optomed Aurora fundus cameras without pupil dilation. The images obtained with the handheld fundus camera had a field of view of 50° and 5 mega-pixel resolution.
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in local shear stress in brachial artery.
In order to calculate local shear stress in brachial artery, measurements of mean flow velocity in the lumen of these arteries will be needed. These measurements will be obtained, while performing carotid ultrasonography in brachial artery, as previously described. In detail, the form to calculate shear stress is: shear stress (in dyn/cm2 ) = 8×μ× mean flow velocity/resting diameter, where μ is the viscosity of blood which was assumed to be 0.035 dyne s/cm2
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Circulating biomarkers of myocardial stress and injury will include N-terminal pro-B-type natriuretic peptide (NT-proBNP). Venous blood samples will be collected after standard clinical preparation, processed according to local laboratory procedures, and analyzed in the hospital's certified biochemistry laboratory using automated immunoassays.
NT-proBNP will be measured as a marker of myocardial wall stress and reported in pg/mL. Values will be interpreted according to established clinical thresholds. In the non-acute setting, NT-proBNP <125 pg/mL will be considered within the normal range, whereas values ≥125 pg/mL will be considered elevated and suggestive of increased myocardial stress. For descriptive analyses, higher-risk thresholds may also be reported, including ≥300 pg/mL and age-adjusted categories when appropriate.
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in high-sensitivity cardiac troponin (hs-cTn).
High-sensitivity cardiac troponin will be measured as a marker of myocardial injury and reported in ng/L. Venous blood samples will be collected after standard clinical preparation, processed according to local laboratory procedures, and analyzed in the hospital's certified biochemistry laboratory using automated immunoassays.
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in serum phosphate
Serum phosphate will be measured in certified clinical laboratories using standard clinical procedures and reported in mg/dL.
Measured: For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.
Differences between PTH-treated group, disease control group, and healthy controls in albumin-adjusted serum calcium
Albumin-adjusted serum calcium will be measured in certified clinical laboratories using standard clinical procedures and reported in mg/dl
Measured: For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.
Differences between PTH-treated group, disease control group, and healthy controls in serum magnesium
Serum magnesium will be measured in certified clinical laboratories using standard clinical procedures and reported in mg/dL.
Measured: For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.
Differences between PTH-treated group, disease control group, and healthy controls in serum intact parathyroid hormone (PTH)
Serum intact parathyroid hormone (PTH) will be measured in certified clinical laboratories using standard clinical procedures and reported in pg/mL.
Measured: For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.
Differences between PTH-treated group, disease control group, and healthy controls in serum 25-hydroxyvitamin D
Serum 25-hydroxyvitamin D [25(OH)D] will be measured in certified clinical laboratories using standard clinical procedures and reported in ng/mL.
Measured: For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.
Differences between PTH-treated group, disease control group, and healthy controls in left ventricular global longitudinal strain (GLS)
Left ventricular global longitudinal strain (GLS) will be assessed by speckle-tracking transthoracic echocardiography using standard apical views according to current echocardiographic recommendations. GLS will be reported as percentage (%).
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in left ventricular ejection fraction (LVEF)
Left ventricular ejection fraction (LVEF) will be measured by transthoracic echocardiography using the biplane Simpson's method and reported as percentage (%).
Measured: For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline, 12 months.
Differences between PTH-treated group, disease control group, and healthy controls in left ventricular diastolic function (E/E')
Left ventricular diastolic function will be evaluated by Doppler and tissue Doppler echocardiography. The E/E' ratio will be calculated using transmitral early diastolic inflow velocity (E) and the mean early diastolic mitral annular velocity (E').
Measured: For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline, 12 months.
Differences between PTH-treated group, disease control group, and healthy controls in Augmentation Index (AIx)
Non-invasive estimation of aortic pressure waveforms and reflected waves by pulse wave analysis (PWA) will be performed in the Angiology laboratory by the SphygmoCor System (AtCor Medical Pty Ltd, Sydney, Australia). The radial artery is gently and steadily compressed against the underlying bone, thus flattening it and equalizing circumferential pressures, allowing radial pressure waves to be recorded by a high fidelity micromanometer placed on the tip of a hand - held tonometer the size of a pen (Millar). Optimal recording is obtained if the wrist is bent outward and supported by using a small cushion or the operator's hand. Non-invasive estimation of augmentation index (AIx) normalized to a heart rate of 75 bpm using pulse wave analysis (SphygmoCor System). AIx is expressed as a percentage of central aortic pulse pressure.
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in Central Systolic Blood Pressure
Non-invasive estimation of aortic pressure waveforms and reflected waves by pulse wave analysis (PWA) will be performed in the Angiology laboratory by the SphygmoCor System (AtCor Medical Pty Ltd, Sydney, Australia). The radial artery is gently and steadily compressed against the underlying bone, thus flattening it and equalizing circumferential pressures, allowing radial pressure waves to be recorded by a high fidelity micromanometer placed on the tip of a hand - held tonometer the size of a pen (Millar). Optimal recording is obtained if the wrist is bent outward and supported by using a small cushion or the operator's hand. Central systolic blood pressure measured non-invasively by pulse wave analysis using the SphygmoCor System.
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in Central Diastolic Blood Pressure
Non-invasive estimation of aortic pressure waveforms and reflected waves by pulse wave analysis (PWA) will be performed in the Angiology laboratory by the SphygmoCor System (AtCor Medical Pty Ltd, Sydney, Australia). The radial artery is gently and steadily compressed against the underlying bone, thus flattening it and equalizing circumferential pressures, allowing radial pressure waves to be recorded by a high fidelity micromanometer placed on the tip of a hand - held tonometer the size of a pen (Millar). Optimal recording is obtained if the wrist is bent outward and supported by using a small cushion or the operator's hand. Central diastolic blood pressure measured non-invasively by pulse wave analysis using the SphygmoCor System.
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in Time to Reflected Wave
Non-invasive estimation of aortic pressure waveforms and reflected waves by pulse wave analysis (PWA) will be performed in the Angiology laboratory by the SphygmoCor System (AtCor Medical Pty Ltd, Sydney, Australia). The radial artery is gently and steadily compressed against the underlying bone, thus flattening it and equalizing circumferential pressures, allowing radial pressure waves to be recorded by a high fidelity micromanometer placed on the tip of a hand - held tonometer the size of a pen (Millar). Optimal recording is obtained if the wrist is bent outward and supported by using a small cushion or the operator's hand. Time to the beginning of the reflected wave, measured in milliseconds by pulse wave analysis using the SphygmoCor System.
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in Blood Pressure Amplification
Non-invasive estimation of aortic pressure waveforms and reflected waves by pulse wave analysis (PWA) will be performed in the Angiology laboratory by the SphygmoCor System (AtCor Medical Pty Ltd, Sydney, Australia). The radial artery is gently and steadily compressed against the underlying bone, thus flattening it and equalizing circumferential pressures, allowing radial pressure waves to be recorded by a high fidelity micromanometer placed on the tip of a hand - held tonometer the size of a pen (Millar). Optimal recording is obtained if the wrist is bent outward and supported by using a small cushion or the operator's hand. Blood pressure amplification, calculated as the ratio of peripheral pulse pressure to central pulse pressure using pulse wave analysis.
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences in the Ankle-brachial index (ABI), between PTH-treated group, disease control group, and healthy controls
The primary non-invasive test for the diagnosis of lower extremity artery disease (LEAD) is the ABI. Furthermore, The ABI is a strong marker of CVD and is predictive of cardiovascular events and mortality (28-30). A cut-off value of <0.9 will be used for the diagnosis of LEAD and as predictive index of atherosclerosis, associated with increased risk of cardiovascular morbidity and mortality as previously described (28, 29). Also, a cut-off value of >1.40 will be used as an index of stiffened arteries, also associated with increased mortality, as previously described (30). For its measurement, a 10-12 cm sphygmomanometer cuff will be placed just above the ankle and a (handheld) Doppler instrument (5-10 MHz) will measure the pressure of the posterior and anterior tibial arteries of each foot. The highest ankle systolic pressure will be divided by the highest brachial systolic pressure, resulting in an ABI per leg.
Measured: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline, to 3 and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2026
- Study start1 Apr 2026
- Primary completion1 Apr 2027 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic HypoparathyroidismStudies of the same condition, open and under way.
- More trials run by National and Kapodistrian University of AthensThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 210 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National and Kapodistrian University of Athens
- Sponsor type
- University, hospital or other
- Collaborators
- 251 Hellenic Air Force & VA General Hospital, Alexandra Hospital, Athens, Greece, G.Gennimatas General Hospital, Laikο General Hospital, Athens, Korgialenio-Benakio Red Cross Hospital, AHEPA University Hospital, 424 General Military Hospital, Hippocration General Hospital, KAT General Hospital, Evangelismos Hospital
- Responsible party
- Principal investigator, Maria Yavropoulou, National and Kapodistrian University of Athens
- Investigators
- Kimon Stamatelopoulos, MD, Study director, Medical School, National and Kapodistrian University of Athens
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07707479
- Sponsor's protocol ID
- 112_30/3/2026
- Acronym
- PaTH CV
- Status last verified
- Jul 2026
- First submitted
- 19 Apr 2026
- Last updated
- 16 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Only IPD used in the results publication
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Long-acting PTH Analogues on Markers of Subclinical Arterial and Myocardial Injury in Chronic Hypoparathyroidism..
- ClinicalTrials.gov ID
- NCT07707479
- Acronym / sponsor ID
- PaTH CV / 112_30/3/2026
- Conditions
- Chronic Hypoparathyroidism
- Keywords
- chronic Hypoparathyroidism, palopegteriparatide, subclinical arterial and myocardial injury, cardiovascular disease, concomitant diseases, conventional therapy
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 210 participants (estimated)
- Lead sponsor
- National and Kapodistrian University of AthensUniversity, hospital or other
- Collaborators
- 251 Hellenic Air Force & VA General Hospital, Alexandra Hospital, Athens, Greece, G.Gennimatas General Hospital, Laikο General Hospital, Athens, Korgialenio-Benakio Red Cross Hospital, AHEPA University Hospital, 424 General Military Hospital, Hippocration General Hospital, KAT General Hospital, Evangelismos Hospital
- Study start
- 1 Apr 2026 (actual)
- Primary completion
- 1 Apr 2027 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 16 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to evaluate cardiovascular effects of long-acting parathyroid hormone (PTH) analogues in adults with chronic hypoparathyroidism. The main questions it aims to answer are:
- Do patients with hypoparathyroidism have increased arterial stiffness and markers of subclinical cardiovascular injury compared to healthy individuals?
- Does treatment with a long-acting PTH analogue improve vascular and cardiac function over time compared to conventional therapy? This is a multi-center study with two parts: a cross-sectional comparison and a 12-month prospective follow-up. Adults with chronic hypoparathyroidism and matched healthy controls will undergo clinical evaluation, vascular measurements, cardiac imaging, and blood tests.
In the prospective part, patients that just started long-acting PTH analogue therapy based on their treating physicians choice will be followed for 12 months, with repeat assessments at baseline, 3 months, and 12 months to evaluate changes in cardiovascular markers.
Detailed description
The goal of this study is to better understand how chronic hypoparathyroidism affects heart and blood vessel health, and whether treatment with a long-acting parathyroid hormone (PTH) analogue can improve cardiovascular function. Hypoparathyroidism is a rare condition in which the body does not produce enough PTH, leading to low calcium levels and possible long-term complications, including an increased risk of cardiovascular disease.
This study aims to answer the following main questions:
Do people with chronic hypoparathyroidism have early (subclinical) signs of damage to the heart and blood vessels compared to people without the condition? Does treatment with a long-acting PTH analogue improve vascular health and reduce early markers of cardiovascular disease over time?
The study includes two parts. In the first part, researchers will compare adults with hypoparathyroidism-either receiving standard treatment (calcium and vitamin D) or long-acting PTH therapy-with healthy individuals of similar age and health characteristics. Participants that will undergo the non-invasive tests to assess blood vessel stiffness, blood pressure, microcirculation, and heart function, along with blood tests to measure calcium balance and cardiovascular biomarkers, as part of routine clinical practice will be eligible for the study.
In the second part, participants with hypoparathyroidism who are starting treatment with a long-acting PTH analogue will be followed for 12 months. They will be evaluated at the beginning of the study, at 3 months and again at 12 months. Researchers will track changes in blood vessel function, heart performance, and biochemical markers to determine whether restoring normal PTH levels improves cardiovascular health.
All participants will undergo detailed clinical assessments, including imaging of blood vessels and the heart, as well as laboratory testing. The findings from this study may help improve understanding of cardiovascular risk in hypoparathyroidism and guide future treatment strategies.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Patients with chronic hypoparathyroidism under conventional treatment (disease control) | – | Diagnostic Test: Arterial stiffness in the aorta by measurement of pulse wave velocity, Diagnostic Test: Central blood pressures and reflected waves in the aorta, Diagnostic Test: Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques, Diagnostic Test: Imaging of the sublingual microcirculation (GlycoCheck system), Diagnostic Test: Ankle-brachial index (ABI), Diagnostic Test: Fundoscopy, Diagnostic Test: Cardiac Ultrasonography Study, Diagnostic Test: Local shear stress in brachial and carotid artery, Diagnostic Test: Peripheral and aortic office and ambulatory blood pressure, Diagnostic Test: Circulating levels of myocardial biomarkers, Diagnostic Test: Evaluation of Calcium metabolism20-30 Hypo-PT patients aged ≥18 on conventional HypoPT therapy with any dose of activated vitamin D and calcium and native vitamin D supplements for at least 12 months |
| Patients with chronic hypoparathyroidism under treatment with palopegteriparatide | – | Diagnostic Test: Arterial stiffness in the aorta by measurement of pulse wave velocity, Diagnostic Test: Central blood pressures and reflected waves in the aorta, Diagnostic Test: Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques, Diagnostic Test: Imaging of the sublingual microcirculation (GlycoCheck system), Diagnostic Test: Ankle-brachial index (ABI), Diagnostic Test: Fundoscopy, Diagnostic Test: Cardiac Ultrasonography Study, Diagnostic Test: Local shear stress in brachial and carotid artery, Diagnostic Test: Peripheral and aortic office and ambulatory blood pressure, Diagnostic Test: Circulating levels of myocardial biomarkers, Diagnostic Test: Evaluation of Calcium metabolism40-50 Hypo-PT patients aged ≥18 treated with Palopegteriparatide (TransCon PTH) for at least 12 months |
| Healthy controls | – | Diagnostic Test: Arterial stiffness in the aorta by measurement of pulse wave velocity, Diagnostic Test: Central blood pressures and reflected waves in the aorta, Diagnostic Test: Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques, Diagnostic Test: Imaging of the sublingual microcirculation (GlycoCheck system), Diagnostic Test: Ankle-brachial index (ABI), Diagnostic Test: Fundoscopy, Diagnostic Test: Cardiac Ultrasonography Study, Diagnostic Test: Local shear stress in brachial and carotid artery, Diagnostic Test: Peripheral and aortic office and ambulatory blood pressure, Diagnostic Test: Circulating levels of myocardial biomarkers, Diagnostic Test: Evaluation of Calcium metabolismHealthy controls: 170 Healthy controls matched with group 1 and group 2 for age, sex, CVD presence, propensity score, DM2, renal function, BMI and SBP, retrospectively recruited from the Athens Angiometabolic Cohort |
| Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide | – | Diagnostic Test: Arterial stiffness in the aorta by measurement of pulse wave velocity, Diagnostic Test: Central blood pressures and reflected waves in the aorta, Diagnostic Test: Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaques, Diagnostic Test: Imaging of the sublingual microcirculation (GlycoCheck system), Diagnostic Test: Ankle-brachial index (ABI), Diagnostic Test: Fundoscopy, Diagnostic Test: Cardiac Ultrasonography Study, Diagnostic Test: Local shear stress in brachial and carotid artery, Diagnostic Test: Peripheral and aortic office and ambulatory blood pressure, Diagnostic Test: Circulating levels of myocardial biomarkers, Diagnostic Test: Evaluation of Calcium metabolism20 patients starting treatment with palopegteriparatide, previously on conventional treatment |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy or palopegteriparatide for more than one year and comparable healthy individuals, matched to patients based on key characteristics such as age, sex, and cardiovascular risk factors
Key inclusion criteria (2 listed)
- Cross sectional arm: Baseline State: Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy or palopegteriparatide for more than one year
- -Prospective Follow-up: Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy and about to start treatment with palopegteriparatide willing to undergo baseline measurements (prior to the first dose) and repeat measurements at 3 and 12 months.
Key exclusion criteria (7 listed)
- Renal Function: CKD Stage 3 or higher (eGFR < 60 mL/min/1.73 m²)
- Uncontrolled Risk Factors:
- Bone Health: Any metabolic bone disease other than hypoparathyroidism (excluding osteoporosis)
- Documented Atrial Fibrillation (ECG)
- Contraindication to long acting PTH analogue as per product labeling
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Arterial stiffness in the aorta by measurement of pulse wave velocityCarotid-femoral pulse wave velocity (c-f PWV) is an established index of aortic stiffness and an independent predictor of worse cardiovascular prognosisIt is considered as the gold standard for assessing aortic stiffness non-invasively and is calculated from measurements of pulse transit time and the distance travelled between 2 recording sites with a validated non-invasive device (Complior, Artech Medical, France). Two different pulse waves are obtained at the same time transcutaneously with the patient in a supine position at 2 sites, at the right common carotid artery and the right femoral artery (i.e. 'carotid-femoral' PWV) by using pressure-sensitive transducers. | Diagnostic test | Healthy controls, Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide, Patients with chronic hypoparathyroidism under conventional treatment (disease control), Patients with chronic hypoparathyroidism under treatment with palopegteriparatide |
| Central blood pressures and reflected waves in the aortaNon-invasive estimation of aortic pressure waveforms and reflected waves by pulse wave analysis (PWA) will be performed in the Angiology laboratory by the SphygmoCor System (AtCor Medical Pty Ltd, Sydney, Australia). The radial artery is gently and steadily compressed against the underlying bone, thus flattening it and equalizing circumferential pressures, allowing radial pressure waves to be recorded by a high fidelity micromanometer placed on the tip of a hand - held tonometer the size of a pen (Millar). Optimal recording is obtained if the wrist is bent outward and supported by using a small cushion or the operator's hand. The following indices are measured: 1. augmentation index (AI, percentage) normalized for the heart rate of 75 bpm, expressed as a percentage of the aortic pulse pressure, 2. central systolic and diastolic pressures (cBP), 3. time to the beginning of the reflected wave (in milliseconds) and 4. blood pressure amplification calculated as the ratio of peripheral | Diagnostic test | Healthy controls, Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide, Patients with chronic hypoparathyroidism under conventional treatment (disease control), Patients with chronic hypoparathyroidism under treatment with palopegteriparatide |
| Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaquesB-mode ultrasound examination will also be performed, using a 14.0 MHz multi-frequency linear array probe attached to a high-resolution ultrasound machine (Vivid 7 Pro, GE Healthcare, USA). All scans are going to be performed by the same operator. Carotid intima-media thickness (ccIMT) will be measured at the distal 1.0 cm of the common carotid proximal to the bifurcation as previously described (23) . In each segment 3 measurements of the maximal IMT in the far wall will be averaged, after excluding plaque thickness. The average of the maximal IMT will be used in the analyses. Femoral IMT (fIMT) will be measured on each side, scanning a 1cm-long arterial segment proximal to the femoral bifurcation, defined as the common femoral artery segment and the average value of IMT of the far wall will be estimated. A cutoff value of >0.9 mm for mean ccIMT or fIMT will be considered increased. Plaques to carotid and femoral arteries are defined as a focal structure that protrudes into the arteri | Diagnostic test | Healthy controls, Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide, Patients with chronic hypoparathyroidism under conventional treatment (disease control), Patients with chronic hypoparathyroidism under treatment with palopegteriparatide |
| Imaging of the sublingual microcirculation (GlycoCheck system)The measurement procedure and the calculation of the sublingual microvascular parameters is performed as follows: the probe of a hand-held side-stream darkfield (SDF) videomicroscope (CapiScope HVCS, KK Technology, Honiton, UK) is placed on the sublingual mucosa of the subject, to obtain video recordings of the sublingual microvasculature. Subsequently, an analysis software (the GlycoCheck Measurement System Software Version 5.3.3) selects and analyses SDF images that are of sufficient quality (adequate focus, adequate contrast and limited movement) and automatically calculates the sublingual microcirculation parameters, such as vascular density (VD), red blood cell filling (RBCF), and perfused boundary region (PBR). | Diagnostic test | Healthy controls, Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide, Patients with chronic hypoparathyroidism under conventional treatment (disease control), Patients with chronic hypoparathyroidism under treatment with palopegteriparatide |
| Ankle-brachial index (ABI)The primary non-invasive test for the diagnosis of lower extremity artery disease (LEAD) is the ABI. A cut-off value of <0.9 will be used for the diagnosis of LEAD and as predictive index of atherosclerosis, associated with increased risk of cardiovascular morbidity and mortality. Also, a cut-off value of >1.40 will be used as an index of stiffened arteries, also associated with increased mortality. For its measurement, a 10-12 cm sphygmomanometer cuff will be placed just above the ankle and a (handheld) Doppler instrument (5-10 MHz) will measure the pressure of the posterior and anterior tibial arteries of each foot. The highest ankle systolic pressure will be divided by the highest brachial systolic pressure, resulting in an ABI per leg. | Diagnostic test | Healthy controls, Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide, Patients with chronic hypoparathyroidism under conventional treatment (disease control), Patients with chronic hypoparathyroidism under treatment with palopegteriparatide |
| FundoscopyA set of colour and black-and-white fundus images photograph per eye will be taken by well-trained ophthalmic photographers: macula-centered images using the handheld Optomed Aurora fundus cameras without pupil dilation. The images obtained with the handheld fundus camera had a field of view of 50° and 5 mega-pixel resolution | Diagnostic test | Healthy controls, Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide, Patients with chronic hypoparathyroidism under conventional treatment (disease control), Patients with chronic hypoparathyroidism under treatment with palopegteriparatide |
| Cardiac Ultrasonography StudyParticipants will undergo a baseline echocardiographic examination. Standard protocol will be used and standard measurements from 2-D and Doppler echocardiography will be made. LV end-diastolic and end-systolic volumes, as well as ejection fraction, will be derived from the apical 4- and 2-chamber views using the biplane Simpson's rule. Left ventricular mass will be calculated according to Devereux's formula. Doppler examination will include interrogation of mitral inflow, and early (E) and late (A) peak diastolic velocities and deceleration time will be measured. Tissue Doppler analysis will include pulse wave interrogation of the medial and lateral mitral annulus, peak diastolic early E΄ annular velocities will be obtained and the mean value and E/E' will be calculated. In addition, Speckle-tracking analysis will be applied to estimate LV rotational mechanics, and longitudinal strain parameters. Parasternal short-axis views at the level of the mitral valve and apex, and standard apic | Diagnostic test | Healthy controls, Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide, Patients with chronic hypoparathyroidism under conventional treatment (disease control), Patients with chronic hypoparathyroidism under treatment with palopegteriparatide |
| Local shear stress in brachial and carotid arteryIn order to calculate local shear stress in brachial and carotid artery, measurements of mean flow velocity in the lumen of these arteries will be needed. These measurements will be obtained, while performing carotid ultrasonography and FMD in brachial artery, as previously described. In detail, the form to calculate shear stress is: shear stress (in dyn/cm2 ) = 8×μ× mean flow velocity/resting diameter, where μ is the viscosity of blood which was assumed to be 0.035 dyne s/cm2 | Diagnostic test | Healthy controls, Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide, Patients with chronic hypoparathyroidism under conventional treatment (disease control), Patients with chronic hypoparathyroidism under treatment with palopegteriparatide |
| Peripheral and aortic office and ambulatory blood pressureThe peripheral and aortic office blood pressure will be assessed using specialized equipment (certified blood pressure monitor). 24-hour Ambulatory Blood pressure monitoring for measurement of 24 hour peripheral and aortic | Diagnostic test | Healthy controls, Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide, Patients with chronic hypoparathyroidism under conventional treatment (disease control), Patients with chronic hypoparathyroidism under treatment with palopegteriparatide |
| Circulating levels of myocardial biomarkersFasting venous blood samples will be collected for evaluation of myocardial biomarkers (hs-troponin I, NT-proBNP). Additional samples will be obtained for isolation of PBMCs. | Diagnostic test | Healthy controls, Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide, Patients with chronic hypoparathyroidism under conventional treatment (disease control), Patients with chronic hypoparathyroidism under treatment with palopegteriparatide |
| Evaluation of Calcium metabolismFasting venous blood samples will be collected for evaluation of calcium metabolism (PTH, calcium, albumin, magnesium, phosphate, 25-hydroxyvitamin D) . | Diagnostic test | Healthy controls, Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide, Patients with chronic hypoparathyroidism under conventional treatment (disease control), Patients with chronic hypoparathyroidism under treatment with palopegteriparatide |
Primary outcome
Differences between PTH-treated group, disease control group, and healthy controls in carotid-femoral pulse wave velocity (cfPWV)
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline, to 3 and 12 months
Differences in carotid-femoral pulse wave velocity (cfPWV) between patients with hypoparathyroidism receiving conventional therapy, patients treated with long-acting PTH analogue (palopegteriparatide/TransCon PTH), and healthy controls. Two different pulse waves are obtained at the same time transcutaneously with the patient in a supine position at 2 sites, at the right common carotid artery and the right femoral artery (i.e. 'carotid-femoral' PWV) by using pressure-sensitive transducers. The distance traveled by the pulse wave is measured over the body surface and calculated by subtracting the carotid (sternal notch from the carotid)-femoral distance as distance/time (m/s) .
22 secondary outcomes
Differences between PTH-treated group, disease control group, and healthy controls in central blood pressure
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline, to 3 and 12 months
Differences between PTH-treated group, disease control group, and healthy controls in peripheral blood pressure
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline, to 3 and 12 months
Differences between PTH-treated group, disease control group, and healthy controls in carotid intima-media thickness (IMT)
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in sublingual microcirculation parameters (vascular density)
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in fundoscopic vascular findings.
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in local shear stress in brachial artery.
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in high-sensitivity cardiac troponin (hs-cTn).
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in serum phosphate
Time frame: For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.
Differences between PTH-treated group, disease control group, and healthy controls in albumin-adjusted serum calcium
Time frame: For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.
Differences between PTH-treated group, disease control group, and healthy controls in serum magnesium
Time frame: For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.
Differences between PTH-treated group, disease control group, and healthy controls in serum intact parathyroid hormone (PTH)
Time frame: For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.
Differences between PTH-treated group, disease control group, and healthy controls in serum 25-hydroxyvitamin D
Time frame: For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.
Differences between PTH-treated group, disease control group, and healthy controls in left ventricular global longitudinal strain (GLS)
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in left ventricular ejection fraction (LVEF)
Time frame: For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline, 12 months.
Differences between PTH-treated group, disease control group, and healthy controls in left ventricular diastolic function (E/E')
Time frame: For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline, 12 months.
Differences between PTH-treated group, disease control group, and healthy controls in Augmentation Index (AIx)
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in Central Systolic Blood Pressure
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in Central Diastolic Blood Pressure
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in Time to Reflected Wave
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences between PTH-treated group, disease control group, and healthy controls in Blood Pressure Amplification
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months
Differences in the Ankle-brachial index (ABI), between PTH-treated group, disease control group, and healthy controls
Time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline, to 3 and 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
- Individual participant dataSharing planned: Yes. Only IPD used in the results publication
Related trials for Chronic Hypoparathyroidism
RecruitingPhase 3
Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism
Hypoparathyroidism, Chronic Hypoparathyroidism
RecruitingPhase 3
A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism
Hypoparathyroidism
RecruitingPhase 2
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder
RecruitingObservational study
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
Obesity and Obesity-related Medical Conditions, Diabetes
RecruitingObservational study
Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
Neurodevelopmental Disorders, Neurodevelopmental Disorders (NDD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kimon Stamatelopoulos, MD study director
Medical School, National and Kapodistrian University of Athens
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Hypoparathyroidism, run by National and Kapodistrian University of Athens at 2 sites in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Differences between PTH-treated group, disease control group, and healthy controls in carotid-femoral pulse wave velocity (cfPWV) (time frame: For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline, to 3 and 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.